Results For "Biocon-Q4FY26-results"

1 News Found

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

Biopharma | May 08, 2026

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations

Latest Stories

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

Dr. Reddy’s and Nestle Health Science launch Celevida GLP for optimized nutritional support

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Kavinder Beniwal Chief Operational Officer, Motorica India

Packaging